This trial will study whether obicetrapib is effective and safe in people with familial hypercholesterolemia or ASCVD.
0 Primary · 9 Secondary · Reporting Duration: Percent change from baseline to Day 84, Day 180, and Day 365 in TC
Experimental Treatment
Non-Treatment Group
2400 Total Participants · 2 Treatment Groups
Primary Treatment: Obicetrapib · Has Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Illinois | 66.7% |
Arizona | 33.3% |
18 - 65 | 100.0% |
Did not meet criteria | 66.7% |
Met criteria | 33.3% |
Biofortis, Inc | 100.0% |
1 | 50.0% |
3+ | 50.0% |